國元國際:重磅產品開始商業化,予東曜藥業-B(1875.HK)“買入”評級
國元國際發研報稱,商業化的重磅產品及發展迅速的CDMO業務將推動東曜藥業-B(1875.HK)業績和流動性將會大大改善,再次覆蓋給予買入評級,予目標價6.04港元。2021年東公司有3款產品在中國獲批上市,分別為用於治療晚期、轉移性或者複發性非鱗狀非小細胞肺癌和轉移性結直腸癌的貝伐珠單抗注射液(樸欣汀)、擁有抗腫瘤活性的烷化劑的仿製藥替莫唑胺膠囊(替至安)、可有效改善艾滋病和癌症患者的惡病質狀態的醋酸甲地孕酮口服混懸液(美適亞)。其中美適亞為國內首個獲批上市的高濃度醋酸甲地孕酮口服混懸液。總體來説,產品增長潛力巨大。
另外,公司CDMO/CMO業務實現收入5369萬元,同比上升736%,新增訂單突破1億元,其中ADC項目訂單佔比約60%,項目數量較2020年增長3倍左右,預計CDMO業務今年有望增長2-3倍。公司競爭優勢明顯,一方面,公司擁有核心偶聯工藝和放大的技術優勢以及ADC關鍵質量屬性的自主分析能力,其中其自研HER2靶向ADC藥物TAA013在ADC領域位於國內第一梯隊;另一方面,產能、產線靈活,商業化佈局完善,使得公司可以提供小試、中試及商業化等不同規模的CDMO服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.